Literature DB >> 33174329

Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving Emicizumab.

Connie H Miller1, Brian Boylan1, Amanda B Payne1, Jennifer Driggers1, Christopher J Bean1.   

Abstract

Entities:  

Year:  2020        PMID： 33174329      PMCID： PMC8077731          DOI： 10.1111/ijlh.13384

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN： 1751-5521            Impact factor:   2.877


× No keyword cloud information.
  10 in total

1.  Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance.

Authors:  C H Miller; S J Platt; A S Rice; F Kelly; J M Soucie
Journal:  J Thromb Haemost       Date:  2012-06       Impact factor: 5.824

Review 2.  Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A.

Authors:  Jens Müller; Isabell Pekrul; Bernd Pötzsch; Beate Berning; Johannes Oldenburg; Michael Spannagl
Journal:  Thromb Haemost       Date:  2019-06-16       Impact factor: 5.249

Review 3.  Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.

Authors:  C H Miller
Journal:  Haemophilia       Date:  2018-02-15       Impact factor: 4.287

4.  Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.

Authors:  B Boylan; A S Rice; A L Dunn; M D Tarantino; D B Brettler; J C Barrett; C H Miller
Journal:  J Thromb Haemost       Date:  2014-12-11       Impact factor: 5.824

5.  Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors.

Authors:  C H Miller; B Boylan; A D Shapiro; S R Lentz; B M Wicklund
Journal:  J Thromb Haemost       Date:  2017-09-14       Impact factor: 5.824

6.  Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays.

Authors:  Joanne I Adamkewicz; David C Chen; Ido Paz-Priel
Journal:  Thromb Haemost       Date:  2019-05-07       Impact factor: 5.249

7.  Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.

Authors:  Annette Bowyer; Steve Kitchen; Rhona Maclean
Journal:  Haemophilia       Date:  2020-04-06       Impact factor: 4.287

8.  Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study.

Authors:  C H Miller; A S Rice; B Boylan; A D Shapiro; S R Lentz; B M Wicklund; F M Kelly; J M Soucie
Journal:  J Thromb Haemost       Date:  2013-07       Impact factor: 5.824

9.  Community counts: Evolution of a national surveillance system for bleeding disorders.

Authors:  Marilyn J Manco-Johnson; Vanessa R Byams; Michael Recht; Becky Dudley; Brandi Dupervil; Diane J Aschman; Meredith Oakley; Suzanne Kapica; Mariam Voutsis; Steven Humes; Roshni Kulkarni; Althea M Grant
Journal:  Am J Hematol       Date:  2018-04-28       Impact factor: 10.047

10.  Detection and IgG subclass analysis of antibodies to factor VIII in multitransfused haemophiliacs and healthy individuals.

Authors:  P Gautier; Y Sultan; A Parquet-Gernez; F Meriane; C Guerois; A Derlon
Journal:  Haemophilia       Date:  1996-04       Impact factor: 4.287
  10 in total
  2 in total

1.  Acquired hemophilia following COVID-19 vaccination: Case report and review of literature.

Authors:  Michiel Happaerts; Thomas Vanassche
Journal:  Res Pract Thromb Haemost       Date:  2022-09-09

Review 2.  An Update on Laboratory Diagnostics in Haemophilia A and B.

Authors:  Jens Müller; Wolfgang Miesbach; Florian Prüller; Thomas Siegemund; Ute Scholz; Ulrich J Sachs
Journal:  Hamostaseologie       Date:  2022-02-01       Impact factor: 2.145
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.